The research team, led by Fadwa M. Arafa and colleagues, set out to test whether olibanum, the oleogum resin better known as frankincense, harvested from Boswellia trees, could work together with Bacillus clausii, a spore-forming bacterium long used in human medicine as a probiotic, to combat intestinal cryptosporidiosis in immunosuppressed mice. The logic of the pairing is appealing on several levels. Olibanum has a long ethnopharmacological history and contains a rich mixture of terpenoids and other bioactive molecules with documented anti-inflammatory and antimicrobial properties. Bacillus clausii, meanwhile, is remarkably resilient, surviving gastric acid as dormant spores and then germinating in the intestine, where it can modulate the local immune environment and compete with pathogens. Combining a directly acting phytochemical with an immune-modulating probiotic is a rational strategy for a disease in which both the parasite burden and the host’s inflammatory damage matter.

Before any efficacy testing, the investigators characterized the chemistry of their olibanum extract using liquid chromatography coupled to mass spectrometry, a sensitive analytical technique that separates complex mixtures and identifies individual components by their mass and fragmentation behavior. The analysis revealed that the extract was dominated by isomers of incensole, a diterpenoid compound that has attracted growing scientific interest for its anti-inflammatory and even psychoactive properties. Knowing the dominant constituents matters for reproducibility and for future mechanistic work: if the extract proves effective, incensole isomers become the leading candidates for the active principle, and standardized preparations can be developed around them rather than relying on variable crude resin.

The efficacy experiments were structured around groups of mice rendered immunosuppressed, mimicking the clinical situation in patients with HIV/AIDS, transplant recipients on immunosuppressive drugs, or children with malnutrition-related immune impairment. After infection with Cryptosporidium, the animals received either olibanum extract alone, Bacillus clausii alone, the two together, or no specific therapy. The primary parasitological endpoint was the number of oocysts, the parasite’s environmentally resistant transmission stage, shed in the feces. Oocyst shedding is the standard measure of parasite burden in this model and also the direct source of environmental contamination, so reducing it has both therapeutic and epidemiological significance.

The results were striking. By the nineteenth day after infection, the combination therapy had reduced fecal oocyst counts by 98.4 percent, the highest reduction recorded in the study. Bacillus clausii alone achieved an 87.6 percent reduction, and olibanum alone came in close behind at 87 percent. Each treatment was therefore clearly active on its own, but the combination outperformed both, providing quantitative evidence of synergy between the resin extract and the probiotic. A reduction of this magnitude, if it translates to humans, would be clinically meaningful even by the standards of modern antiparasitic chemotherapy, and it was achieved without the toxicity concerns that limit some existing drugs.

To understand how the treatments were killing or disabling the parasite, the researchers turned to scanning electron microscopy, which allows visualization of the oocysts’ surface architecture at extremely high magnification. Oocysts from mice treated with olibanum or Bacillus clausii individually showed a consistent pattern of ultrastructural damage: the normally smooth, ovoid structures became shrunken and deformed, with extensive pits and protrusions marring their surfaces. Such damage is more than cosmetic, because the oocyst wall is the parasite’s armor against the outside world and must remain intact for the organism to survive passage to a new host and to excyst successfully in the next intestine. The most dramatic finding, however, came from the combination group, where the oocysts were not merely deformed but completely distorted and ruptured, their walls destroyed outright. This graded progression of damage, from subtle surface changes with single agents to catastrophic wall failure with the combination, is a compelling visual signature of the synergistic mechanism at work.

The study went beyond parasite killing to examine the biochemical state of the infected animals. Cryptosporidium infection, like many intestinal infections, generates oxidative stress, a state in which reactive oxygen species damage cellular lipids, proteins, and DNA. One standard marker of this lipid damage is malondialdehyde, or MDA, whose serum levels rise as peroxidation proceeds. The antioxidant defense enzyme system, meanwhile, depends on molecules such as reduced glutathione, or GSH, which neutralize those reactive species. In the treated mice, both olibanum and Bacillus clausii, whether given alone or in combination, lowered serum MDA and raised mean GSH levels. In other words, the treatments did not just reduce the parasite load; they also shifted the host’s internal chemistry back toward a protected, antioxidant state, which likely contributes to the healing of the intestinal lining.

Histopathological examination of the intestine provided the structural counterpart to these biochemical findings. Cryptosporidium colonizes the surface of the small intestinal epithelium, where its presence blunts and distorts the villi, the finger-like projections that multiply the absorptive area of the gut, and disrupts the mucus-secreting goblet cells that form part of the mucosal barrier. The consequence is malabsorption, diarrhea, and weight loss, the clinical hallmarks of severe cryptosporidiosis. In the study, the best histological outcomes were observed after the combined olibanum and Bacillus clausii treatment, which restored the normal villus architecture, markedly ameliorated the detrimental intestinal inflammation, and improved goblet cell counts. The combination therefore did not merely suppress the parasite; it actively promoted the regeneration of the tissue that the parasite had damaged, a distinction that matters enormously for patients whose symptoms persist even when parasite counts fall.

Perhaps the most intriguing results came from immunohistochemical analysis of the lymphocyte populations within the intestinal villi. By staining tissue sections for CD4 and CD8 markers, the researchers could quantify the balance between helper T cells, which coordinate immune responses, and cytotoxic T cells, which kill infected cells. Treatment with olibanum, Bacillus clausii, or the combination produced a statistically significant rise in the CD4-positive to CD8-positive ratio compared with untreated infected animals. A higher CD4 to CD8 ratio signals a rebalancing of the mucosal immune response toward the helper-driven coordination that is essential for clearing protozoal infections, and it is particularly notable given that the animals were immunosuppressed. The probiotic component plausibly drives much of this immune modulation, since Bacillus species are known to interact with gut-associated lymphoid tissue, but the study’s design suggests that olibanum contributes as well, whether through its incensole-rich chemistry or through reducing the parasite-driven inflammatory burden.

Taken together, the parasitological, ultrastructural, biochemical, histopathological, and immunological data tell a coherent story. Olibanum extract and Bacillus clausii each impair Cryptosporidium oocysts and ease the oxidative and inflammatory damage of infection, but together they achieve near-total suppression of oocyst shedding, outright rupture of the parasite’s transmission stage, and the most complete restoration of gut structure and immune balance. The findings, published on 30 September 2026, position this resin-plus-probiotic pairing as a promising candidate for further development against a disease for which therapeutic options remain thin. Important caveats remain before any clinical translation: the work was performed in mice, doses and safety in immunosuppressed humans must be established, and the specific active molecules in olibanum need to be identified and standardized. Still, the study exemplifies a growing trend in antimicrobial research, the rational combination of plant-derived compounds with live biotherapeutics, and it offers a glimmer of hope for the immunocompromised patients who currently have the fewest options against this persistent intestinal parasite.

Subject of Research: Combination therapy with olibanum extract and Bacillus clausii against intestinal cryptosporidiosis in immunosuppressed mice

Article Title: Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice

Article References: Arafa, F. M., Hagar, M., Zakaria, A., Sheta, E., & Hezema, N. N. (2026). Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice. PLOS Neglected Tropical Diseases, 20(9), e0014734. https://doi.org/10.1371/journal.pntd.0014734

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014734

Keywords: cryptosporidiosis, Cryptosporidium, olibanum, frankincense, Bacillus clausii, probiotics, immunosuppressed mice, oocyst reduction, incensole, oxidative stress, intestinal histopathology, CD4/CD8 ratio